Krystal Biotech (KRYS) Pipeline Narrative Keeps Valuation In Focus After Recent Run Up
Krystal Biotech (KRYS) stock has been drawing attention after recent gains, with the share price closing at $359.36 on 29 August 2026. Investors are weighing this move against the company’s broader return profile and fundamentals.
The move to $359.36 comes after a steady upswing, with a 7 day share price return of 5.16% adding to a 90 day share price return of 22.56% and a 1 year total shareholder return of 143.30%, which points to strong positive momentum for Krystal Biotech as investors reassess both growth prospects and risk.
Scan how Krystal Biotech’s momentum compares with other high quality stocks using the hand picked 45 high quality undervalued stocks list for ideas beyond this one biotech.
After a rise of more than 140% over the past year and a recent close at $359.36, some investors see Krystal Biotech as just getting started, while others see most of the upside already priced in. How does the current valuation stack up against the fundamentals?
Most Popular Narrative: 6.7% Undervalued
Krystal Biotech’s most followed valuation narrative pegs fair value at $385, slightly above the last close at $359.36, which puts recent gains into context.
The expansion of Krystal's pipeline, including imminent and near-term clinical readouts in lung disease (AATD, CF), ophthalmology, oncology (NSCLC), and aesthetics, leverages increased R&D productivity, which could drive future revenue growth and diversify earnings beyond a single product.
Want to see what is baked into that $385 figure? The narrative focuses on rapid revenue growth, wider margins, and a future earnings multiple that assumes continued execution across several new indications. You may want to consider which assumptions carry the most weight in that model.
Result: Fair Value of $385 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Krystal Biotech’s story can change quickly if VYJUVEK revenue proves volatile or if key ophthalmology and lung trial readouts underwhelm expectations.
Find out about the key risks to this Krystal Biotech narrative.
Another Way To Look At Krystal Biotech’s Valuation
The SWS DCF model paints a very different picture to the $385 fair value narrative. At a last close of $359.36, Krystal Biotech is shown as trading well below an estimated future cash flow value of $1,803.92 per share, which frames the stock as heavily undervalued. Which set of assumptions do you find more credible?
Look into how the SWS DCF model arrives at its fair value.
Next Steps
Given the mix of enthusiasm and caution around Krystal Biotech right now, it makes sense to move quickly, check the numbers for yourself, and weigh both sides of the story using the 3 key rewards and 1 important warning sign
Looking for more investment ideas beyond Krystal Biotech?
If you stop with just one stock, you might miss opportunities that suit your goals better. Use the Simply Wall Street Screener to broaden your watchlist.
- Target income-focused opportunities and review companies that appear in the 12 dividend fortresses for potential yield ideas that match your risk comfort.
- Focus on financial resilience by scanning the list of solid balance sheet and fundamentals (52 results) to find businesses with stronger balance sheets and fundamentals.
- Identify potential up-and-comers early and sift through the 19 high quality undiscovered gems before these companies attract wider attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com